Indigo Diabetes N.V. (Indigo) is a pioneering developer of medical devices for people living with chronic diseases. Using its proprietary nanophotonics technology the Company is developing the world’s first subcutaneously implanted Continuous Multi-Metabolite Monitoring (CMM®) sensor to provide people living with chronic diseases access to information on their metabolite levels at any time, without the need to wear an external device on their body. Indigo is initially focused on diabetes to address the need for continuous and accurate glucose, ketone, and lactate monitoring. Indigo is headquartered in Ghent, Belgium, and also has employees based in the US.